Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
54 studies found for:    physical | urticaria
Show Display Options
RSS Create an RSS feed from your search for:
physical | urticaria
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
2 Recruiting Chronic Urticaria - Long Term Assessment of Effects of Rupatadine
Condition: Chronic Urticaria
Interventions: Drug: 10 mg Rupatadine on demand;   Drug: 10 mg Rupatadine;   Drug: 20 mg Rupatadine;   Drug: 10 mg Rupatadine on demand (sham updosing to 20 mg)
3 Completed An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
Condition: Urticaria
Intervention: Drug: Desloratadine
4 Completed Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Condition: Urticaria
Interventions: Drug: Bilastine;   Drug: Levocetirizine;   Drug: Placebo
5 Completed
Has Results
Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
6 Completed
Has Results
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Condition: Idiopathic Solar Urticaria
Interventions: Drug: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209);   Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211);   Drug: bisoctrizole 10% alone (formula RV3131A-MV1237);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213);   Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329);   Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)];   Drug: V0096 CR vehicle (formula RV3131A-MV1197)
7 Active, not recruiting The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
Condition: Chronic Urticaria
Intervention: Other: CU-Q2oL
8 Completed Phase II Solar Urticaria (SU) Pilot Study
Condition: Solar Urticaria
Intervention: Drug: afamelanotide
9 Unknown  Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
Condition: Urticaria
Intervention: Drug: omalizumab
10 Completed Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test
Condition: Chronic Urticaria
Intervention: Other: Urticaria Control Test
11 Completed Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
Condition: Urticaria
Interventions: Drug: Cetirizine;   Drug: Desloratadine;   Drug: Fexofenadine;   Drug: Ebastine;   Drug: Bilastine
12 Recruiting Cold Contact Urticaria Treatment With Rilonacept
Condition: Cold Contact Urticaria
Interventions: Drug: Rilonacept;   Drug: Placebo
13 Completed Bilastine Updosing in Chronic Spontaneous Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Bilastine;   Drug: Bilastin
14 Completed
Has Results
Urticaria Facticia Treatment With Omalizumab (UFO)
Condition: Symptomatic Dermographism
Interventions: Drug: Omalizumab;   Drug: Placebo
15 Not yet recruiting Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria
Condition: Chronic Spontaneous Urticaria
Interventions: Drug: Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.;   Drug: Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
16 Terminated Efficacy of Rupatadine 5, 10 and 20 Mg in Chronic Idiopathic Urticaria
Condition: Urticaria
Intervention: Drug: RUPATADINE (ANTI-HISTAMINE)
17 Completed Bilastine Updosing - Characterization of Underlying Mechanisms
Condition: Cold Contact Urticaria
Intervention: Drug: Bilastine
18 Completed Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria
Condition: Urticaria
Intervention: Drug: Alesion®
19 Completed Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Conditions: Urticaria;   Vasculitis
Intervention: Drug: canakinumab
20 Completed OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
Condition: Chonic Spontaneous Urticaria
Intervention: Drug: omalizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.